Table 2.

Side Effects by Exposure at week-6 and Treatment Group^a

	SSRIb				Venlafaxine
Total No. Participants	< GMc		≥ GM		< GM		≥ GM
	49		76		44		75
	N	%	N	%	N	%	N	%
Appetite Disturbance	22	44.9	26	34.2	21	47.7	37	49.3
Cardiovasculard	19	38.8	27	35.5	14	31.8	46	61.3
Central Nervous System	38	77.6	57	75.0	36	81.8	64	85.3
Dermatologye	11	22.4	12	15.8	9	20.5	31	41.3
Dizziness Standing Upf	12	24.5	23	30.3	12	27.3	41	54.7
Gastrointestinal	35	71.4	43	56.6	29	65.9	53	70.7
Genito-Urinary	5	10.2	6	7.9	3	6.8	9	12.0
Headache	29	59.2	49	64.5	25	56.8	55	73.3
Irritability/Anger	27	55.1	46	60.5	26	59.1	52	69.3
Lethargy/Apathy	20	40.8	29	38.2	16	36.4	29	38.7
Mouth/Nose	24	49.0	33	43.4	23	52.3	36	48.0
Muskulo-Skeletal	15	30.6	23	30.3	14	31.8	28	37.3
Ocular	6	12.2	9	11.8	5	11.4	10	13.3
Sleep Disturbances	34	69.4	46	60.5	35	79.5	56	74.7

^aAdverse effects reported by at least 5% of TORDIA participants on the Side Effects Form for Children and

Adolescents. No statistically significant differences unless otherwise noted.

^bCitalopram (n=27), fluoxetine (n=64), or paroxetine (n=34).

^cGM = Geometric Mean.

^dVenlafaxine: χ²₁ =9.66, P=.002.

^eVenlafaxine: χ²₁ =5.42, P=.02.

^fVenlafaxine: χ²₁ =8.43, P=.004.